These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 29314439)

  • 1. Low incidence of factor VIII inhibitors in previously untreated patients with severe haemophilia A treated with octanate
    Klukowska A; Komrska V; Vdovin V; Pavlova A; Jansen M; Lowndes S; Belyanskaya L; Walter O; Laguna P
    Haemophilia; 2018 Mar; 24(2):221-228. PubMed ID: 29314439
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low incidence of factor VIII inhibitors in previously untreated patients during prophylaxis, on-demand treatment and surgical procedures, with Octanate®: interim report from an ongoing prospective clinical study.
    Klukowska A; Komrska V; Jansen M; Laguna P
    Haemophilia; 2011 May; 17(3):399-406. PubMed ID: 21118334
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical efficacy of a novel VWF-containing FVIII concentrate, Wilate(®), in the prophylaxis and treatment of bleeding episodes in previously treated haemophilia A patients.
    Klukowska A; Windyga J; Batorova A
    Thromb Res; 2011 Mar; 127(3):247-53. PubMed ID: 21220152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A postmarketing surveillance study of the safety and efficacy of ReFacto (St Louis-derived active substance) in patients with haemophilia A.
    Smith MP; Giangrande P; Pollman H; Littlewood R; Kollmer C; Feingold J;
    Haemophilia; 2005 Sep; 11(5):444-51. PubMed ID: 16128886
    [TBL] [Abstract][Full Text] [Related]  

  • 5. octanate
    Klukowska A; Komrska V; Vdovin V; Zozulya N; Lissitchkov T; Oldenburg J; Ettingshausen CE
    Ther Adv Hematol; 2020; 11():2040620720914692. PubMed ID: 32341775
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity, efficacy and safety of Nuwiq
    Liesner RJ; Abashidze M; Aleinikova O; Altisent C; Belletrutti MJ; Borel-Derlon A; Carcao M; Chambost H; Chan AKC; Dubey L; Ducore J; Fouzia NA; Gattens M; Gruel Y; Guillet B; Kavardakova N; El Khorassani M; Klukowska A; Lambert T; Lohade S; Sigaud M; Turea V; Wu JKM; Vdovin V; Pavlova A; Jansen M; Belyanskaya L; Walter O; Knaub S; Neufeld EJ
    Haemophilia; 2018 Mar; 24(2):211-220. PubMed ID: 28815880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical assessment of Optivate®, a high-purity concentrate of factor VIII with von Willebrand factor, in the management of patients with haemophilia A.
    Dmoszynska A; Kuliczkowski K; Hellmann A; Trelinski J; Kloczko J; Baglin T; Hay C; O'Shaughnessy D; Zawilska K; Makris M; Shaikh-Zaidi R; Gascoigne E; Dash C
    Haemophilia; 2011 May; 17(3):456-62. PubMed ID: 21371184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Re: low incidence of factor VIII inhibitors in PUPs during prophylaxis, on-demand treatment and surgical procedures, with Octanate®: interim report from an ongoing prospective clinical study.
    Ewenstein BM; Reininger AJ
    Haemophilia; 2011 Sep; 17(5):e847-8. PubMed ID: 21752157
    [No Abstract]   [Full Text] [Related]  

  • 9. Postauthorization safety surveillance of ADVATE [antihaemophilic factor (recombinant), plasma/albumin-free method] demonstrates efficacy, safety and low-risk for immunogenicity in routine clinical practice.
    Oldenburg J; Goudemand J; Valentino L; Richards M; Luu H; Kriukov A; Gajek H; Spotts G; Ewenstein B
    Haemophilia; 2010 Nov; 16(6):866-77. PubMed ID: 20579113
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence and risk factors for inhibitor development in previously untreated severe haemophilia A patients born between 2005 and 2010.
    Vézina C; Carcao M; Infante-Rivard C; Lillicrap D; Stain AM; Paradis E; Teitel J; Rivard GE;
    Haemophilia; 2014 Nov; 20(6):771-6. PubMed ID: 25039669
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Occurrence of inhibitors in previously untreated or minimally treated patients with haemophilia A after exposure to a plasma-derived solvent-detergent factor VIII concentrate.
    Gringeri A; Monzini M; Tagariello G; Scaraggi FA; Mannucci PM;
    Haemophilia; 2006 Mar; 12(2):128-32. PubMed ID: 16476086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stability, efficacy, and safety of continuously infused sucrose-formulated recombinant factor VIII (rFVIII-FS) during surgery in patients with severe haemophilia.
    Martinowitz U; Luboshitz J; Bashari D; Ravid B; Gorina E; Regan L; Stass H; Lubetsky A
    Haemophilia; 2009 May; 15(3):676-85. PubMed ID: 19298381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First prospective report on immune tolerance in poor risk haemophilia A inhibitor patients with a single factor VIII/von Willebrand factor concentrate in an observational immune tolerance induction study.
    Kreuz W; Escuriola Ettingshausen C; Vdovin V; Zozulya N; Plyushch O; Svirin P; Andreeva T; Bubanská E; Campos M; Benedik-Dolničar M; Jiménez-Yuste V; Kitanovski L; Klukowska A; Momot A; Osmulskaya N; Prieto M; Šalek SZ; Velasco F; Pavlova A; Oldenburg J; Knaub S; Jansen M; Belyanskaya L; Walter O; ;
    Haemophilia; 2016 Jan; 22(1):87-95. PubMed ID: 26202305
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Zero incidence of factor VIII inhibitors and successful haemostatic response in previously factor VIII-treated patients with haemophilia A switching to turoctocog alfa in a noninterventional study.
    Escuriola Ettingshausen C; Katsarou O; Kotnik BF; Borel Derlon A; Schwarz R; Ypma PF; Matytsina I; Dey S; Schutgens REG
    Haemophilia; 2022 Jan; 28(1):46-54. PubMed ID: 34791736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The clinical efficacy and safety of the FVIII/VWF concentrate, BIOSTATE®, in children with von Willebrand disorder: a multi-centre retrospective review.
    Howman R; Barnes C; Curtin J; Price J; Robertson J; Russell S; Seldon M; Suppiah R; Teague L; Barrese G
    Haemophilia; 2011 May; 17(3):463-9. PubMed ID: 21118340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extended half-life pegylated, full-length recombinant factor VIII for prophylaxis in children with severe haemophilia A.
    Mullins ES; Stasyshyn O; Alvarez-Román MT; Osman D; Liesner R; Engl W; Sharkhawy M; Abbuehl BE
    Haemophilia; 2017 Mar; 23(2):238-246. PubMed ID: 27891721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of turoctocog alfa in the prevention and treatment of bleeds in previously untreated paediatric patients with severe haemophilia A: Results from the guardian 4 multinational clinical trial.
    Yaish H; Matsushita T; Belhani M; Jiménez-Yuste V; Kavakli K; Korsholm L; Matytsina I; Philipp C; Reichwald K; Wu R
    Haemophilia; 2020 Jan; 26(1):64-72. PubMed ID: 31816159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective surveillance study of haemophilia A patients switching from moroctocog alfa or other factor VIII products to moroctocog alfa albumin-free cell culture (AF-CC) in usual care settings.
    Parra Lopez R; Nemes L; Jimenez-Yuste V; Rusen L; Cid AR; Charnigo RJ; Baumann JA; Smith L; Korth-Bradley JM; Rendo P
    Thromb Haemost; 2015 Oct; 114(4):676-84. PubMed ID: 26293201
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Experience of Advate rAHF-PFM in previously untreated patients and minimally treated patients with haemophilia A.
    Auerswald G; Thompson AA; Recht M; Brown D; Liesner R; Guzmán-Becerra N; Dyck-Jones J; Ewenstein B; Abbuehl B
    Thromb Haemost; 2012 Jun; 107(6):1072-82. PubMed ID: 22476554
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy, safety and pharmacokinetic profiles of a plasma-derived VWF/FVIII concentrate (VONCENTO®) in subjects with haemophilia A (SWIFT-HA study).
    Skotnicki A; Lissitchkov TJ; Mamonov V; Buevich E; Kuliczkowski K; Goranov S; Kłoczko J; Klukowska A; Stankovic S; Gercheva L; Chernova T; Hellmann A; Dmoszyńska A; Zawilska K; Veldman A; Joch C; Seifert W
    Thromb Res; 2016 Jan; 137():119-125. PubMed ID: 26614676
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.